TABLE 1

Characteristics of the subjects, the parameter values from regression analysis based on a mechanism-based CYP2C8 inhibition model, and the observed maximum fold increase in repaglinide AUC_0-∞, when 0.25 mg of repaglinide was given to each subject 1 h after a single 30-, 100-, 300-, or 900-mg dose of gemfibrozil, compared with placebo

Subject no.	Age	Sex	Weight	BMI	CYP2C8 Genotype	SLCO1B1 Genotype	Gemfibrozil 1-O-β-Glucuronide C_h,u/C_p,tot	Repaglinide f_m,CYP2C8	Repaglinide Maximum AUC_i/AUC_c
	yr		kg	kg/m²
1	26	Male	64	21	1/1	1A/1A	0.325	0.880	7.7
2	25	Male	84	26	1/1	1A/15	0.063	0.880	6.0
3	25	Male	68	22	1/1	1A/1B	0.330	0.886	8.2
4	21	Male	67	21	1/1	1A/1B	0.189	0.865	7.0
5	24	Male	60	21	1/1	1A/1A	0.228	0.911	9.9
6	20	Female	67	24	1/1	1A/1B	0.118	0.886	7.6
7	24	Male	82	27	1/1	1A/15	0.501	0.897	8.9
8	21	Male	82	23	3/3	1A/15	0.239	0.915	10.8
9	22	Male	88	25	1/1	1A/1A	0.519	0.838	6.0
10	22	Male	72	24	1/3	1B/15	0.334	0.915	11.4
Mean ± S.D.	23 ± 2		73 ± 10	23 ± 2			0.285 ± 0.149	0.887 ± 0.024	8.4 ± 1.9

BMI, body mass index.